ELECTROMED, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.98 USD | +1.28% |
|
+2.53% | +37.31% |
| 05-07 | Transcript : Electromed, Inc., Q3 2024 Earnings Call, May 07, 2024 | |
| 05-07 | Electromed, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 | CI |
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Sales forecast by analysts have been recently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With an expected P/E ratio at 29.37 and 24.56 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +37.31% | 130M | C | ||
| +9.55% | 222B | B | ||
| +14.41% | 196B | B- | ||
| +24.02% | 148B | B- | ||
| +33.92% | 114B | A- | ||
| +5.17% | 65.69B | A- | ||
| +12.92% | 51.88B | B+ | ||
| +3.16% | 50.02B | B+ | ||
| -4.32% | 38.81B | A | ||
| -1.99% | 34.59B | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ELMD Stock
- Ratings Electromed, Inc.
